Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Zentalis Pharmaceuticals is supported by a compelling biomarker-driven thesis for azenosertib, as DENALI Part 1b showed cyclin E1-positive patients achieved a median overall survival of 15.8 to 15.9 months versus 7.5 months in cyclin E1-negative patients, with an updated ORR of 37.2% and no new safety signals. The company’s improving tolerability profile, including roughly half the prior treatment-related discontinuation rate to about 10% in Part 2a, strengthens confidence that the 400 mg QD 5:2 regimen can serve as an oral non-chemotherapy option in heavily pretreated PROC. Its $228.9 million cash balance, net loss of $28.8 million in Q3, and funding into 1H:28 provide runway ahead of the DENALI Part 2 topline expected in 1H:27 and the ASPENOVA confirmatory program.

Zentalis Pharmaceuticals is exposed to substantial binary risk because its valuation depends heavily on azenosertib, and any clinical or regulatory failure could materially weaken the investment case. The company’s lead asset may not prove sufficiently efficacious, safety signals could halt development, and commercial adoption may be challenged by current and future therapies. As a clinical-stage biopharmaceutical company with no diversified product revenue base disclosed here, its ability to achieve sales estimates remains uncertain and highly dependent on successful development and market acceptance.